This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n27http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/resource/AHFS/
n20http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n8http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/genbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/uniprotkb/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/patent/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n17http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00103/identifier/drugbank/
n26http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00103
rdf:type
n3:Drug
n3:description
Recombinant human alpha-galactosidase A. The mature protein is composed of 2 subunits of 398 residues. Protein is glycosylated and produced by CHO cells
n3:dosage
n14:271B4548-363D-11E5-9242-09173F13E4C5 n14:271B4549-363D-11E5-9242-09173F13E4C5 n14:271B454A-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Schaefer RM, Tylki-Szymanska A, Hilz MJ: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19852524 # El Dib RP, Pastores GM: Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20464743 # Lim-Melia ER, Kronn DF: Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009 Aug;38(8):448-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19725195
n3:group
investigational approved
n3:halfLife
45-102 min
n3:indication
For treatment of Fabry's disease (alpha-galactosidase A deficiency)
owl:sameAs
n8:DB00103 n16:DB00103
dcterms:title
Agalsidase beta
adms:identifier
n12:Agalsidase_beta n13:PA164746527 n18:X14448 n23:DB00103 n24:P06280 n25:58468-0040-1
n3:mechanismOfAction
Alpha-galactosidase A catalyzes the hydrolysis of globotriaosylceramide (GL-3) and other a-galactyl-terminated neutral glycosphingolipids, such as galabiosylceramide and blood group B substances to ceramide dihexoside and galactose.
n3:packager
n4:271B4545-363D-11E5-9242-09173F13E4C5 n4:271B4544-363D-11E5-9242-09173F13E4C5
n3:patent
n15:2265464
n3:synonym
Alpha-D-galactosidase A Alpha-galactosidase A precursor Alpha-D- galactoside galactohydrolase Melibiase Agalsidase alfa
n5:hasAHFSCode
n6:44-00-00
n19:hasConcept
n20:M0430431
foaf:page
n22:agalsidase-beta.html n27:fabrazyme.htm
n3:Molecular-Formula
n17:271B454E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n17:271B454D-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n26:A16AB04
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
104138-64-9
n3:category
n3:clearance
* 4.1 +/- 1.2 mL/min/kg [adult patients with Fabry disease,0.3 mg/kg, 1 infusion] * 4.6 +/- 2.2 mL/min/kg [adult patients with Fabry disease, 0.3 mg/kg, 5 infusions] * 2.1 +/- 0.7 mL/min/kg [adult patients with Fabry disease, 1 mg/kg, 1 infusion] * 3.2 +/- 2.6 mL/min/kg [adult patients with Fabry disease, 1 mg/kg, 5 infusions] * 0.8 +/- 0.3 mL/min/kg [adult patients with Fabry disease, 3 mg/kg, 1 infusion] * 0.8 +/- 0.4 mL/min/kg [adult patients with Fabry disease, 3 mg/kg, 5 infusions] * 1.8 +/- 0.8 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 1-3 infusions] * 4.9 +/- 5.6 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 7 infusions] * 2.3 +/- 2.2 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 11 infusions]
n3:containedIn
n9:271B4546-363D-11E5-9242-09173F13E4C5 n9:271B4547-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n17:271B454B-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n17:271B454C-363D-11E5-9242-09173F13E4C5